Skip to main content

A fair price for drugs

DSC08197
iStock Drugs image for commentary

In January we published quarterly and monthly reports. Both of them included thoughts on the changing healthcare market. We return to the topic again only three months later. But this is no surprise. It’s a colossal industry which is grappling with major demographic shifts. And it has profound implications for our health and happiness.This time the spotlight falls on a specific part of the health market: drugs. Drugs are around 10% to 15% of total healthcare spending1 in most developed economies. Their prices have grown broadly in line with other healthcare costs2. Those costs have themselves grown much faster than inflation.

This isn’t supposed to happen. When drugs’ patents expire, they should be open to generic competition. There will always be new higher-priced patented drugs. But overall, the promise was that drugs would be a smaller piece of the pie.

This contradiction has been in focus for a while. In the USA, it is playing out in the political arena. The starting gun for serious scrutiny was a Hillary Clinton tweet in September 20153. She attacked price gouging by specialty pharmaceutical companies. Their share prices have never really recovered.

Donald Trump would never like to agree with Hillary on anything. Despite this, in due course he too joined the fight. His flagship “Blueprint to Lower Drug Prices” launched in May 20184. This included a range of measures, some more sensible than others.

In March this year, the debate moved to the political centre stage. Just before the month started, leaders from large drug-makers were grilled in a Senate hearing. Just after the month end, their counterparts from the firms that buy drugs for patients gave their side of the story. The testimony was wide-ranging. But some tentative steps towards change have now come into view. The first moves are towards greater price transparency.

This is a welcome direction but on its own won’t keep a lid on prices. For that, you really need meaningful buyer power. That’s why we invest in some of the companies that deliver that, such as CVS, Centene and Premier. They consolidate demand to negotiate lower prices.

This is the model followed by single-buyer systems around the world, such as the NHS here in the UK. But before we outside the US congratulate ourselves on figuring out a better way, there is a deeper question to consider. Developing new drugs is very expensive, now often more than $1bn for an individual therapy. If the drug-makers can’t earn a return on that investment, they will lose the incentive to innovate.

March also provided a good example of this tension. Drug-maker Vertex has a new cystic fibrosis drug called Orkambi. It is a lifesaver. It dramatically slows the decline in lung function that is a leading cause of death among cystic fibrosis sufferers. But it is expensive: Vertex wants the NHS to pay at least £104,000 per patient per year. The NHS can only offer £14,0005.

With around 3,000 people6 who could benefit from Orkambi watching on, the issue has moved into our own political arena. In March, a Parliamentary Health and Social Care Committee Inquiry gathered evidence7. The Ministry is now considering its response.

Over the last few decades, innovation in pharmaceuticals has improved lives for everyone on the planet. But sharing the costs and benefits fairly is a real challenge. That is the key reason why our strategy has had very limited exposure to drug-makers in the last ten years.

We have selective exposures where these issues of pricing are less critical. This includes in generics, through Fresenius, and plasma-based therapies, through CSL. We invest in buyer-power companies as mentioned earlier. We also invest in some companies which can help to use technology to deliver better outcomes, such as Cerner. But otherwise we’re waiting for a more sustainable business model for drug-making to develop.

1 https://www.drugcostfacts.org/us-healthcare-spending

2 https://www.healthsystemtracker.org/chart-collection/recent-forecasted-trends-prescription-drug-spending/#item-annual-growth-in-rx-drug-spending-and-total-health-spending-per-capita_nhe-projections-2018-27

3 https://www.forbes.com/sites/steveschaefer/2015/09/21/hillary-clinton-biotech-stocks-election/#51bd38553f87

4 https://www.whitehouse.gov/briefings-statements/president-donald-j-trumps-blueprint-lower-drug-prices/

5 https://news.sky.com/story/orkambi-drugs-maker-says-nhs-undervalues-patient-lives-11442845

6 https://www.cysticfibrosis.org.uk/the-work-we-do/campaigning-hard/life-saving-drugs/orkambi

7 https://www.parliament.uk/business/committees/committees-a-z/commons-select/health-and-social-care-committee/news/orkambi-publication-letter-to-secretary-of-state-17-19/

Important Notices:
Risks include: the price of shares (“Shares”) in FP WHEB Sustainability Impact Fund, WHEB Sustainable Impact Fund or WHEB Environmental Impact Fund may increase or decrease and you may not get back the amount originally invested, for reasons including adverse market and foreign exchange rate movements. Past performance does not predict future returns. The Fund invests in equities and is exposed to price fluctuations in the equity markets, and focuses on investments in mid-sized companies in certain sectors so its performance may not correlate closely with the MSCI World Index (the benchmark). For full risks, please see fund prospectus on www.whebgroup.com

 

General: This information, its contents and any related communication (altogether, the “Information”) is issued by WHEB Asset Management LLP (“WHEB Asset Management”). It is intended for information purposes only and does not constitute or form part of any offer or invitation to buy or sell any security including any shares in the FP WHEB Sustainability Impact Fund or WHEB Sustainable Impact Fund, including in the United States. It should not be relied upon to make an investment decision in relation to Shares in the FP WHEB Sustainability Impact Fund or WHEB Sustainable Impact Fund or otherwise; any such investment decision should be made only on the basis of the Fund scheme documents and appropriate professional advice. This Information does not constitute advice of any kind, investment research or a research recommendation, is in summary form and is subject to change without notice. The performance shown does not take account of any commissions and costs charged when subscribing to and redeeming shares. WHEB Asset Management has exercised reasonable care in preparing this Information including using reliable sources, however, makes no representation or warranty relating to its accuracy, reliability or completeness or whether any future event may or may not occur. This Information is only made available to recipients who may lawfully receive it in accordance with applicable laws, regulations and rules and binding guidance of regulators. WHEB Asset Management LLP is registered in England and Wales with number OC 341489 and has its registered office at 7 Cavendish Square, London, W1G 0PE. WHEB Asset Management LLP is authorised and regulated by the Financial Conduct Authority with Firm Reference Number 496413.

 

FP WHEB Sustainability Impact Fund

FundRock Partners Limited (formerly Fund Partners Limited) is the Authorised Corporate Director of the Fund and is authorised and regulated by the Financial Conduct Authority with Firm Reference Number 469278 and has its registered office at 6th Floor Bastion House, 140 London Wall, London, EC2Y 5DN. The state of the origin of the Fund is England and Wales. The Representative in Switzerland is ACOLIN Fund Services AG, Leutschenbachstrasse 50, CH-8050 Zurich, whilst the Paying Agent is NPB Neue Privat Bank AG, Limmatquai 1/am Bellevue, P.O. Box, 8024 Zurich . The relevant documents such as the prospectus, the key investor information document (KIIDs), the Articles of Association as well as the annual and semi-annual reports may be obtained free of charge from the Representative in Switzerland.

 

WHEB Sustainable Impact Fund

The Manager of the Fund is FundRock Management Company S.A., authorised and regulated by the Luxembourg regulator to act as UCITS management company and has its registered office at 33, rue de Gasperich, L-5826 Hesperange, Grand-Duchy of Luxembourg. The Representative in Switzerland is ACOLIN Fund Services AG, Leutschenbachstrasse 50, CH-8050 Zurich, whilst the Paying Agent is NPB Neue Privat Bank AG, Limmatquai 1/am Bellevue, P.O. Box, 8024 Zurich. The relevant documents such as the prospectus, the key investor information document (KIIDs), the Articles of Association as well as the annual and semi-annual reports may be obtained free of charge from the representative in Switzerland. The state of the origin of the Fund is Ireland. The Fund is registered for distribution to professional investors in Austria, France, Germany, Italy, Luxembourg, Norway, Singapore, Sweden and the United Kingdom, and is registered for offering to retail investors in Switzerland, Denmark and the Netherlands. The Fund is also available for professional investors in Belgium and Hong Kong. It is not available to investors domiciled in the United States.

 

WHEB Environmental Impact Fund

The Manager of the Fund is FundRock Management Company S.A., authorised and regulated by the Luxembourg regulator to act as UCITS management company and has its registered office at 33, rue de Gasperich, L-5826 Hesperange, Grand-Duchy of Luxembourg. The Fund is registered for distribution to professional investors in the United Kingdom. It is not available to investors domiciled in the United States.

 

The MSCI information may only be used for your internal use, may not be reproduced or re-dissseminated in any form and may not be used as a basis for or a component of any financial instruments or products or indices. None of the MSCI information is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such. Historical data and analysis should not be taken as an indication or guarantee of any future performance analysis, forecast or prediction. The MSCI information is provided on an “as is” basis and the user of this information assumes the entire risk of any use made of this information. MSCI, each of its affiliates and each other person involved in or related to compiling, computing or creating any MSCI information (collectively, the “MSCI Parties”) expressly disclaims all warranties (including, without limitation, any warranties of originality, accuracy, completeness, timeliness, non-infringement, merchantability and fitness for a particular purpose) with respect to this information. Without limiting any of the foregoing, in no event shall any MSCI Party have any liability for any direct, indirect, special, incidental, punitive, consequential (including, without limitation, lost profits) or any other damages (www.msci.com).

Sign up to impact fund updates

Sign up below to receive email updates on our impact investment funds.
{{ errors[0] }}
{{ errors[0] }}
{{ errors[0] }}
{{ errors[0] }}
{{ errors[0] }}
{{ errors[0] }}
Authorised and regulated by the Financial Conduct Authority Copyright 2024© WHEB. All rights reserved Made by Thursday